Rubió laboratories signs an agreement with AB BIOTICS for the co distribución Spain of Neurofarmagen r epilepsy.

-400,000 people suffering from epilepsy in Spain and 75-80% can be controlled with proper medication

-this disease involves 4.13% of the expenditure on health in Spain, according to data from the Spanish Foundation of neurological diseases

Barcelona, 2011-August Rubió laboratories has signed an agreement with the biotechnology company AB-BIOTICS for the co-distribución in the Spanish market of Neurofarmagen ® epilepsy, a genetic analysis that allows predict how you will answer the patient to drugs more used in the treatment of this disease.

According to statements by Carlos Rubió and Pelayo Rubió, co-directors laboratories Rubió General this new agreement with AB-BIOTICS will represent a significant increase in global billing at the national level and strengthens the aim of providing unique and innovative products to Spanish physicians. The introduction of Neurofarmagen ® epilepsy to the pharmaceutical market is a breakthrough in personalized medicine ”.

The contract on Neurofarmagen ® epilepsy is the second agreement of distribution between the two companies since last December, when AB-BIOTICS granted laboratories Rubió distribution exclusively in the Spanish market – and the right of preferential option for the granting of rights of distribution in exclusive for GermanyThe Netherlands, United Kingdom, Denmark, Argentina, Canada, New Zealand, Brazil and Mexico – from Neurofarmagen ® ADHD. This genetic analysis allows to know the patient response to major drugs for the treatment of the disorder with hyperactivity (ADHD) attention deficit, and help to assess the risk of developing this disease.

After the success of the first agreement between laboratories Rubió and AB-BIOTICS for the distribution of Neurofarmagen ® ADHD, it has reached a new agreement for codistribuir, on this occasion, Neurofarmagen ® epilepsy.

400,000 epileptics in Spain

Epilepsy is a neurological disease that affects approximately 400,000 Spaniards, and each year are diagnosed between 12,400 and 22,000 new cases according to the Spanish Foundation of neurological diseases study FEEN. The incidence is higher in the first years of life, especially in children aged between 6 and 14. Although it is estimated that you between 5% and 10% of the population will experience a crisis throughout his life, a 75-80% of patients achieved control their seizures with drugs.

Identify the most appropriate treatment is especially important for these patients, as controlling the crisis is essential to lead a normal life in the professional and personal. In this sense, Neurofarmagen ® epilepsy can assess, through a simple analysis of saliva, the willingness of the patient to respond to the drugs most commonly used for the treatment of epilepsy and other related disorders such as West syndrome, Lennox-Gastaut syndrome, Rasmussen syndromeLandau–Kleffner syndrome, the syndrome of tuberous sclerosis, Sturge-Weber Syndrome and Dravet syndrome.

In addition to assuming an improvement in the quality of life of the patient, analysis allows to reduce health spending. It is estimated that epilepsy is 4.13% of the budget allocated to health, according to data from the Spanish Foundation of neurological diseases corresponding to the year 2000.

About laboratories Rubió

Rubió laboratories is a family company founded in 1968 and headquartered in Castellbisbal (Barcelona), dedicated to the production, distribution, marketing and sale of medicines and health products boasts a prestigious commercial network established throughout the Spanish. A pharmaceutical company specializing in serving patients that suffer from low-prevalence diseases. Significant national growth of the company over the years has followed the challenge of international expansion. The firm currently sells various pharmaceutical specialties in many countries of America, Asia, Europe and Africa.

About AB-BIOTICS

AB-BIOTICS is a Spanish biotech company whose business is diversified into four business areas based on the research, development, protection and distribution of own and exclusive, biotechnological solutions with the Mission of improving the health and well-being of people. The company has an innovative philosophy and with an own know-how that allows you to develop cutting-edge products that contribute to the market a high added value.

AB-BIOTICS since last July is the first and only biotechnology company with headquarters in Catalonia and the second at Spain, which is listed in the Stock Exchange alternative market (aim), incorporating the segment of business expansion.